Abstracts tagged "interferons and interleukins (IL)"

Abstract Number: 1121 • 2016 ACR/ARHP Annual Meeting
IFN Regulatory Factor-5 Signaling Increases IFN-Gamma Production and Suppresses IL-2 Production from CD4+ T Cells, and Controls IgG Production in B Cells
Kei Yasuda¹, Prachi Shukla², Ramon G. Bonegio¹ and Ian Rifkin¹, ¹Renal Section, Boston Univ Schl of Med, Boston, MA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies of human genetics and mouse models have shown that interferon regulatory factor-5 (IRF5) is associated with the development of autoimmune disease. However,…
Abstract Number: 1765 • 2013 ACR/ARHP Annual Meeting
Complement Component C5a Permits The Co-Existence Of Pathogenic Th17 Cells and Type I Interferon In Lupus
Marc C. Levesque¹, Sudesh Pawaria², Kelly Maers² and Partha Biswas³, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Dept. of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a type I interferon (IFN-I)-driven autoimmune disorder with exaggerated B and T-helper (Th) cell responses. Th17 cells, a recently…
Abstract Number: 631 • 2013 ACR/ARHP Annual Meeting
Type I IFN Regulation Of IL-10 Is Detrimental To Endothelial Cell Differentiation and May Enhance Cardiovascular Risk In Systemic Lupus Erythematosus
J. Michelle Kahlenberg¹, Alyssa Cates², Victoria Holden³, Carolyne K. Smith⁴ and Mariana J. Kaplan⁵, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Rheumatology and Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease resulting in organ damage and an elevated risk of cardiovascular disease (CVD). Previous reports have suggested…
Abstract Number: 2671 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjögren’s Syndrome
Christopher J. Lessard¹, He Li², Indra Adrianto³, John A. Ice³, Roland Jonsson⁴, Gabor G. Illei⁵, Maureen Rischmueller⁶, Gunnel Nordmark⁷, Xavier Mariette⁸, Corinne Miceli-Richard⁹, Marie Wahren-Herlenius¹⁰, Torsten Witte¹¹, Michael T. Brennan¹², Roald Omdal¹³, Patrick M. Gaffney³, James A. Lessard¹⁴, Wan-Fai Ng¹⁵, Nelson L. Rhodus¹⁶, Barbara M. Segal¹⁷, R. Hal Scofield¹⁸, Judith A. James¹⁹, Juan-Manuel Anaya²⁰, John B. Harley²¹, Courtney G. Montgomery³ and Kathy Moser Sivils¹⁹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway, ⁵Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁶Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁹Hopital Bicêtre, Le Kremlin Bicêtre, France, ¹⁰Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹²Nidcr NIH, Carolinas Medical Center, Charlotte, NC, ¹³Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹⁴Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁵Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ²¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].